HELPING YOU TO IDENTIFY & SUPPORT VULNERABLE PEOPLE · Comentis delivers a digital assessment tool to identify and support vulnerable customers or service users.
Apr 19, 2016 · CoMentis, Inc. has its headquarters in South San Francisco. The company is engaged in the discovery and development of small- molecule drugs ...
CoMentis is a biotech company engaged in the research and development of small molecule drugs to treat neurovascular diseases.
As a team we have always been passionate about using innovation and technology to identify and protect the vulnerable and those at risk.
Developer of small-molecule drugs designed to treat central nervous system disorders. The company's drugs cover the research and development spectrum from ...
CoMentis is focused on developing drugs to treat various central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia.
CoMentis, Inc. develops small molecule drugs. The Company provides drugs for the treatment of central nervous system disorders such as alzheimer disease and ...
Comentis launches equity release mental capacity assessment
ifamagazine.com › comentis-launches-eq...
Feb 23, 2024 · Designed to ensure conveyancers and solicitors are suitably equipped to assess borrowers' mental capacity, Comentis is launching a new capacity ...
Comentis provide a quick and easy-to-use tool that enables the care provider to assess whether a service user has the mental capacity to make a decision around ...
Founded: South San Francisco CA United States (2004). Status: Defunct (2014). CoMentis. Organization Overview. First Clinical Trial.